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Abstract: MicroRNAs (miRNAs) are short sequences of noncoding single-stranded RNAs that exhibit inhibitory effects on complementary target
mRNAs. Recently, it has been discovered that certain viruses express their own miRNAs, while other viruses activate the transcription of cellular miRNAs
for their own benefit. This review summarizes the viral and/or cellular miRNAs that are transcribed during infection, with a focus on the biomarker and
therapeutic potential of miRNAs (or their antagomirs). Several human viruses of clinical importance are discussed, namely, herpesviruses, polyomaviruses,
hepatitis B virus, hepatitis C virus, human papillomavirus, and human immunodeficiency virus.
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Introduction

Several types of small noncoding RNAs have been discovered that affect a multitude of biological pathways within the
cell. One such class includes microRNAs (miRNAs), short
sequences of noncoding single-stranded RNAs that exhibit
inhibitory effects on complementary target mRNAs. Research
on miRNAs can provide insights into the development, treatment, and monitoring of diseases, including viral diseases.
This review aims to provide an overview of recent research
characterizing the role of miRNAs during viral infection.
We focus on several viruses of clinical importance in order
to assess the potential of host- and virus-derived miRNAs as
therapeutic targets or biomarkers of disease.
A biomarker is an objectively measured indicator that
reflects the presence or progression of a particular condition.
In addition, biomarkers can be used to monitor the efficacy of
treatments for a disease. The discovery and validation of novel
biomarkers reduce the time and cost associated with drug
development and therefore increase the success rate of translating experimental drugs into clinical therapeutics.1 They are
a valuable tool to improve animal models of disease, monitor
drug candidate safety and efficacy, and detect changes in the
pathological state of a disease. Biological fluids from the local
site of pathology, known as proximal fluids, often provide a
more accurate assessment of the pathological state. Plasma is
often used for biomarker assessment, due to the ease in obtaining it, and thus, any proximal biomarkers that spill over into
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the bloodstream may prove to be effective biomarkers that are
more easily accessible than proximal fluids.

Biogenesis of miRNAs

Several excellent reviews are available that explain the details
of miRNA biogenesis.2,3 Most miRNAs are transcribed
through the actions of RNA polymerase II from templates
found within introns of protein-coding genes or directly from
independent genes.3,4 In the cytoplasm, the miRNA guide
strand remains associated with Argonaute (Ago) within the
RNA-induced silencing complex (RISC), while the complementary strand, referred to as the miRNA* (star strand) or
passenger strand, is degraded. Unlike most cellular miRNAs,
certain viral miRNAs can be derived from both strands of the
double-stranded miRNA molecule, leading to the convention
of naming the strands with -5p or -3p suffixes.
The guide miRNA is the primary mechanism for targeting the RISC complex to mRNAs. Although miRNAs
are ∼22 nucleotides in length, the mRNA target is generally recognized through complementary base pairing of the
seed sequence comprising nucleotides 2–7 at the 5′ end of
the miRNA strand.5 Consequently, one miRNA:RISC complex can silence hundreds of mRNAs with complementarity
to the same seed sequence, regardless of their translational
products. Once bound by the RISC, miRNAs usually target
the 3′-untranslated region (UTR) of mRNAs,6 resulting in
the repression of translation and/or degradation of the target
Biomarker Insights 2015:10(S4)
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mRNA.3,7 It is now well established that miRNAs influence
an extensive number of biological pathways in this manner
through regulation of protein-coding genes.

Techniques for miRNA Identification and
Verification

Host- and virus-derived miRNAs can be identified computationally using bioinformatics or through functional screening
assays. A variety of bioinformatics programs are now available that predict miRNAs (Table 1). Although bioinformatics has been extremely valuable in bringing together possible
sets of miRNAs and their targets, the advent of relatively
inexpensive next-generation sequencing (deep sequencing) platforms and high-density oligonucleotide arrays has
simplified the functional screening of viral miRNAs. Most
viral miRNAs were initially identified through a modified
rapid amplification of cDNA ends protocol. Briefly, polyacrylamide gel-purified small RNAs were modified with 5′
or 3′ oligonucleotides that functioned as primers for PCR
after reverse transcription and the amplified segments were
cloned and sequenced. Next-generation sequencing techniques have since then replaced the time-consuming process
of cloning and can process millions of sequence reads in parallel. An elegant use of this technique to identify biologically
relevant miRNAs is termed high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation (HITSCLIP). In this process, ultraviolet (UV) irradiation is used
to covalently crosslink Ago-associated miRNAs and target
mRNAs, which are then immunoprecipitated and sequenced.8
This procedure allows for the identification of miRNAs and
their cognate mRNA recognition elements (MREs) that are
directly associated with RISC from cell lines or tissue samples.9 Photoactivatable-ribonucleoside-enhanced crosslinking
and immunoprecipitation (PAR-CLIP) is a related technique
that uses a photoactivatable nucleoside analog, most often
4-thiouridine, which is randomly incorporated into nascent
RNAs.10 The stable crosslinking of PAR-CLIP results in
increased purification of bound miRNA/mRNA duplexes.
However, this technique cannot be performed on primary

t issue samples. Both procedures enhance the precision of
purified biologically relevant miRNAs and their targets that
can then be confirmed in vitro.
Following their identification through bioinformatics
or high-throughput techniques, putative miRNAs and their
targets must be experimentally validated. Luciferase reporter
assays are commonly used to verify direct binding of a miRNA
to a particular mRNA sequence. The 3′-UTR region predicted
to interact with a miRNA target is placed downstream of
the luciferase gene in a reporter construct. The vector is then
transfected into cells alongside an miRNA expression vector
or a control vector, and luciferase expression is reduced if the
miRNA targets the MRE. Site directed mutagenesis or target
protector nucleotides can also be used to verify MRE sequence
complementarity to the miRNA. Antisense oligonucleotides
(molecular sponges) show specificity of a particular miRNA
seed sequence for an MRE by complementary binding to the
miRNA sequence.11 Viral miRNA deletion mutants are also
used to verify the biological function of individual or clusters
of miRNAs.

Biomarker and Therapeutic Potential of miRNAs
During Viral Infection

The majority of known virally encoded miRNAs are found
within DNA viruses that replicate in the nucleus. The first
viral miRNAs discovered were found to be expressed by
Epstein–Barr virus (EBV).12 Since then, the great majority of
miRNAs have been discovered in herpesviruses. A few viral
miRNAs have also been reported in other human DNA virus
families, including polyomaviruses (described below) and possibly adenoviruses (in very low abundance from virus-associated RNAs). In addition, miRNAs have been reported in
DNA viral families that do not infect humans, namely, ascoviruses (Heliothis virescens ascovirus), baculoviruses (Bombyx
mori nuclear polyhedrosis virus), and nimaviruses (white spot
syndrome virus). Notably, miRNAs from human papilloma
viruses (HPVs) have yet to be definitively discovered.
Retroviruses possess a replication stage that involves
nuclear DNA as a result of reverse transcription, and miRNAs

Table 1. Approaches used by miRNA target prediction software tools.

miRmap

Thermodynamic

Evolutionary

Probabilistic

Sequence-based

Reference

X

X

X

X

356

X

6

TargetScan

X

PITA

X

PicTar

X

miRanda

X

359

RNAhybrid

X

360

DIANA-microT

X

EIMMo
PACMIT

357
X

X
X

X

X

358

361
X

362

X

363

Note: Table modified from Charles E. Vejnar, Evgeny M. Zdobnov. miRmap: Comprehensive prediction of microRNA target repression strength. Nucl Acids Res.
2007;40(22):11673–11683, with permission of Oxford University Press under a CC BY 3.0 license.
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have indeed been discovered in a few retroviruses, including
avian leucosis virus subgroup J, African green monkey simian
foamy virus, and bovine leukemia virus.13,14 As will be discussed later, miRNAs have been reported from the human
immunodeficiency virus (HIV)-1 transactivation response
(TAR) RNA of CD4 T cells,15–17 although other studies have
failed to find biologically relevant viral miRNAs from HIV-1or human T-lymphotropic virus-infected cells.18–20
The existence of miRNAs in cytoplasmic RNA viruses
has yet to be detected, and several reasons have been proposed as to why they are unlikely in cytoplasmic viruses.
The nuclear location of Drosha and DGCR8, necessary
for genesis of pre-miRNAs, is one of the leading explanations for this absence. Interestingly, Rouha et al engineered
a nuclear-replicating RNA virus to contain a miRNA-precursor stem-loop sequence element within its RNA genome.
They found that a functional miRNA was produced without
affecting viral replication, 21 implying the possible existence
of Drosha-independent miRNA generation pathways within
the cytoplasm.

Herpesviruses. Herpesviruses are large, double-stran
ded DNA viruses that infect a range of invertebrate and
vertebrate animals. Nine human herpesviruses (HHVs)
exist, possessing genomes of ∼125–230 kb in length. The
great majority of miRNAs reported thus far have been
found in herpesv iruses, and several of the herpesviruses
each encode over 20 predicted miRNAs (many of which
have not yet been shown to be biologically functional). As
DNA viruses that replicate in the nucleus, herpesviruses
have access to the nuclear proteins Drosha and DGCR8
that are necessary for the processing of primary miRNAs
(pri-miRNAs). Several herpesviruses appear to have autoregulatory miRNAs, including those that maintain latency,
while others use miRNAs to modulate cellular responses
during infect ion (Table 2).
Alphaherpesvirinae subfamily members: herpes simplex
virus-1 (HSV-1), herpes simplex virus-2, and varicella zoster
virus. Members of the Alphaherpesvirinae subfamily, herpes
simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2),
are the causative agents of cold sores and genital herpes,

Table 2. Notable herpesvirus-encoded miRNAs.
Herpesvirus

miRNA

mRNA Target

References

HSV-1

miR-H2

ICP0, a transactivator of IE, E, and L genes

31,32

miR-H4

ICP34.5, a neurovirulence factor and immune inhibitor

33

miR-H6

ICP4, a transactivator of E and L genes

31

miR-H2

HSV1-miR-H2 ortholog; represses ICP0

32

miR-H3

ICP34.5

32,38

miR-H4

ICP34.5

32,38

HSV-2

VZV

None reported

EBV

miR-BART2

BALF5, the viral DNA polymerase

12,54

miR-BART3, -BART5,-BART16,

LMP1, a viral gene that promotes cell survival

55–57

miR-BART5, -BART19

Cellular PUMA, a pro-apoptotic gene

55,59

miR-BART2

Cellular MICB, a stress-induced NK cell ligand

55,63

miR-BART18

Cellular CBP, involved in type 1 IFN production

65

miR-UL112

Targets HCMV genes IE1, IE72, UL112/113, UL114, UL120/121

94–96

miR-UL112

Cellular MICB, a stress-induced NK cell ligand

63,101

miR-UL148D

Cellular RANTES, a T cell-attracting chemokine

102

miR-Ro6–1

Antisense to B3 IE ORF; function unknown

104

miR-Ro6–2

Antisense to B2 IE ORF; function unknown

104

miR-Ro6–3

Antisense to B1 IE ORF; function unknown

104

miR-Ro6–4

Function unknown

104

-BART17, -BART19, -BART20

HCMV

HHV-6B

HHV-7

None reported

KSHV

miR-K12–9, miR-K12–7

RTA, the activator of the latent-lytic switch

72,73

miR-K12–1

Cellular p21, involved in cell cycle arrest

82

miR-K12–7

Cellular MICB, a stress-induced NK cell ligand

63

miR-K12–12

Cellular CBP, involved in Type 1 IFN production

65
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respectively. They establish productive (lytic) infection in
epithelial cells and eventually infect sensory neurons, where
they become latent and persist for the lifetime of the host.
The process of virion replication takes ∼18–20 hours
to complete and occurs in three stages corresponding to the
expression of immediate early (IE; α), early (E; β), and late (L; γ)
genes. During latency, there is little detectable transcription of
IE, E, or L genes in infected neurons, even though it is known
that they produce high levels of untranslated latency-associated transcripts (LATs). An unstable spliced 6.3 kb transcript
and two stable LAT introns of 2 kb and 1.5 kb are spliced from
an unstable 8.3 kb primary transcript.22–25 Although protein
products of the LAT gene locus have not been discovered, the
site has been associated with the repression of IE gene transcription and the maintenance of latency.26–28 More recently,
miRNAs of both virus and host origin have been connected
with maintaining HSV-1 or HSV-2 latency.
According to miRBase.org, 29 18 virus-derived premiRNAs have been identified from HSV-1 that encode
27 mature miRNAs. Many of these have been identified
using bioinformatics or sequencing analysis and have yet to be
characterized in functional biological assays. The best characterized miRNAs are HSV1-miR-H1 through miR-H6.
miR-H1 and miR-H6 are located in the LAT promoter, while
miR-H2, miR-H3, miR-H4, and miR-H5 are derived from
the primary LAT transcript (Fig. 1).30
The targets of most HSV-1 miRNAs are still unknown,
but those that have been characterized point to a role in

HSV-1 genome

0

10
TR

20

30

40

50

60

70
U

L

Enlarged view of the
internal repeat sequences,
showing LATs

preventing viral reactivation from latency through regulation of ICP0, ICP34.5, and ICP4 genes. miR-H2 is derived
from the large LAT transcript and is antisense to ICP0.
Transient-transfection assays showed that miR-H2 is able
to downregulate the IE ICP0 protein, 31,32 which functions
as a transactivator of IE, E, and L genes and, consequently,
promotes viral replication. Also derived from the large
LAT transcript, miR-H4 (and possibly miR-H3) inhibits
the expression of ICP34.5, 33 a neurovirulence factor and
L gene product that induces transcription. Similarly, miRH6 can repress the translation of the ICP4 protein, 31 an IE
protein transactivator that is essential for the maximal transcription of E and L genes. By suppressing the transcription
of ICP0, ICP4, and ICP34.5 genes, these LAT-derived or
LAT-associated miRNAs may be a component of maintaining latency and suppressing active viral replication.
The earliest studies of HSV-1 miRNAs described their
roles in maintaining latency. It is now known that many of
these are also present and differentially expressed during productive infection.30,34,35 For example, miR-H1 and miR-H6
are more highly expressed than miR-H2, miR-H3, and miRH4 during productive infection than latency.30 The opposite is
true during latency, implying that miRNA expression plays a
role in controlling the ordered expression of viral genes. Flores
et al took the analysis of HSV-1 miRNA a step further by
examining which of the miRNAs are loaded into the RISC
as an indication of miRNA biological function. Surprisingly,
only nine HSV-1 miRNAs were found to be associated with
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Figure 1. Genomic location of selected HSV-1 pre-miRNAs.
Note: Figure modified from Nicoll MP, Proença JT, Efstathiou S. The molecular basis of herpes simplex virus latency. FEMS Microbiol Rev. 2012;36:684–706
with permission of Oxford University Press on behalf of the Federation of European Microbiological Societies.446
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the RISC. In addition, the miRNAs were found to associate with the RISC at differing rates, 33 suggesting that several
may not be functional. A recent study by Belter et al shows
that miRNAs in high concentration are able to form secondary structures resembling RNA aptamers, 36 molecules whose
specific 3D shapes allow them to bind targets with high affinity in the absence of the RISC.
A recent report indicates that host-derived miRNAs
may also play a role in promoting HSV-1 latency. Pan et al
found that the neuron-expressed miR-138 downregulated
the expression of ICP0. A mutant HSV-1 virus lacking an
ICP0 mRNA site complementary to miR-138 showed a twofold to fourfold decrease in ICP0 protein in neuronal cells.37
Notably, the expression of ICP0 was unchanged in Vero cells
infected with the mutant virus, further emphasizing that cell
type is an important factor in determining the biological relevance of both viral and host miRNAs.
HSV-2 is the causative agent of genital herpes. Although
viral miRNAs are not necessarily conserved between related
viruses, HSV-2 shares ∼85% homology with HSV-1 and has
several miRNAs located at corresponding locations within
its genome. HSV-2 miRNAs often share a high degree of
homology with their HSV-1 counterparts when considering
the seven-base pair seed regions of the miRNAs.30 HSV-2
miRNAs have also been shown to exert similar regulation upon orthologous HSV-2 genes. For example, both
HSV-2 miR-H2 (ie, miR-III) and HSV-1 miR-H2 are able
to repress ICP0.32 Similarly, HSV-2 miR-H3 and miR-H4
(ie, miR-I and miR-II, respectively), which are found in high
copy number in neurons, are complementary to and lead to
the downregulation of ICP34.5.32,38 There are exceptions to
this conservation that demonstrate that the relative expression of each miRNA is not necessarily the same between
the two viruses and that they may differentially regulate the
expression patterns of viral genes. Specifically, miR-H2 is
the most highly expressed miRNA during HSV-1 infection,
while miR-H3 is most abundant during HSV-2 infection.39
Additionally, not all miRNAs are identical between the two
viruses: HSV-2 lacks an ortholog of miR-H1 and the miR-H6
found in HSV-2 uses the 5′ strand of the miRNA duplex,
whereas HSV-1 miR-H6 uses the 3′ strand.30,31 Interestingly,
the seed sequence of the HSV-2 miR-H6 5′ strand is identical to the seed sequence of the HSV-1 miR-H1, although the
targets of either miRNA are currently unknown.30
HSV-2 encodes a total of 18 virus-derived pre-miRNAs
that derive 24 mature miRNAs. HSV-1 miR-H1, miR-H8,
miR-H14, miR-H18, miR-H26, and miR-H27 have no
known HSV-2 counterparts, while HSV-2 uniquely encodes
miR-H9, miR-H10, and miR-H19 through miR-H25.
Varicella zoster virus (VZV; officially HHV-3) is the
final member of the Alphaherpesvirinae subfamily and causes
chickenpox (varicella) during primary infection and shingles (herpes zoster) upon reactivation. The latency program
of VZV is different from that of HSV-1 and HSV-2. VZV

lacks the LAT locus and does not have an RNA transcript
analogous to LAT. In addition, it expresses several proteins
during latency,40 which is not characteristic of HSV-1 and
HSV-2.Deep sequencing of human trigeminal ganglia identified VZV genomic DNA but no VZV-specific miRNAs
during latency.41 In support of this result, it was reported in
the same study that miRNAs were not able to be recovered
from the trigeminal ganglia of rhesus macaques infected
with the related simian varicella virus, although they have
been discovered in other animal varicelloviruses, bovine herpesvirus 1 and suid herpesvirus 1 (Aujeszky’s disease virus/
pseudorabies virus).42–44 It is worth noting, however, that the
miRNAs from suid herpesvirus 1 map to the large latency
transcript and are complementary to IE transactivators EP0
and EP180,43,44 which are homologs of HSV-1 ICP0 and
ICP4.45 It is thus possible that the miRNAs of Suid herpes
virus 1 share conserved function with miRNAs of HSV-1,
but not those of VZV. Computational analyses have predicted
that VZV does not encode any miRNAs,18 although the possibility of VZV miRNAs during productive infection has yet
to be fully examined.
Gammaherpesvirinae subfamily members: EBV and Kaposi’s
sarcoma-associated herpesvirus. EBV (HHV-4) and KSHV
(HHV-8) are the two herpesviruses within the Gammaherpesvirinae subfamily of herpesviruses. Both viruses productively
infect and become latent within lymphocytes or lymphoid tissues, and both can induce transformation of infected cells that
can lead to malignancies.
EBV causes 90% of the cases of mononucleosis in teenagers or adults. The virus is also associated with Burkitt’s
lymphoma (BL), Hodgkin’s lymphoma, primary effusion lymphoma (PEL), nasopharyngeal carcinoma (NPC), and gastric
carcinomas (GaCas).
EBV was the first virus demonstrated to express
miRNAs.12 There are two clusters in the EBV genome that
encode 25 pre-miRNAs that ultimately produce 44 mature
miRNAs. The BamHI fragment H rightward open reading
frame 1 (BHRF1) cluster is found within the BHRF1 locus
and encodes three miRNAs: miR-BHRF1-1, miR-BHRF1-2,
and miR-BHRF1-3. miR-BHRF1-1 is located in the promoter
of BHRF1, whereas miR-BHRF1-2 and miR-HBRF1-3 are
encoded in the 3′-UTR region of the gene. The second cluster
of EBV miRNAs is located within introns of the BamH1-A
region rightward transcript (BART) locus. This cluster encodes
miR-BART1 through miR-BART22, with the exception of
miR-BART2, which is found downstream of the BART locus
between BILF1 and BALF5 genes.46,47
EBV establishes and maintains persistent infection
through a series of transcription programs characterized by
regulated viral gene expression,48 and the expression of certain
miRNAs correlates with the latency program of infected cells.
The first transcription program, known as Latency 3 or the
growth transcription program, occurs when EBV infects a naïve
B cell. This causes the cell to differentiate into a lymphoblast
Biomarker Insights 2015:10(S4)
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and proliferate. As with normally activated B lymphoblasts,
the cell migrates to the lymph node germinal center follicle and
continues to proliferate. It is at this point that the cell switches
to the Latency 2 transcription program, also known as the
default transcription program, which induces cell differentiation that causes the cell to leave as a resting memory B cell.
In the periphery, the Latency 0 program initiates and protein
translation ceases, except during the Latency 1 program, when
the cell divides due to the expression of EBNA1. The process of
productive viral replication and shedding into saliva is provoked
by memory cells that return to the tonsil and undergo differentiation into antibody-producing plasma cells.48
The BHRF1 miRNAs are highly expressed during the
Latency 3 transcription program of infected BL and in lymphoblastoid cell lines (LCLs), which are generated through
EBV infection of resting B cells.49 Studies that created mutant
viruses by introducing mutations into the BHRF1 miRNAs
showed that these miRNAs are involved in contributing to B
cell transformation by promoting cell-cycle progression and
inhibiting apoptosis.50,51 In stark contrast, BHRF1 miRNAs
were not detectable in NPC, PEL, or BL cell lines in Latency
1 or 2 transcription programs, whereas BART miRNAs were
expressed to high levels.49 In addition, NPC and GaCa epithelial tumors exhibited 13- and 8-fold higher expression,
respectively, of BART miRNAs compared to LCLs.52 Taken
together, this suggests that BART miRNAs appear to be preferentially expressed in epithelial cells (such as NPCs), while
they are moderately expressed in B cells and dispensable for in
vitro EBV-induced transformation.53
Several viral and host mRNA targets of EBV miRNAs
have been identified. miR-BART2 is complementary to BALF5
and downregulates the expression of this viral DNA polymerase,12,54 and miR-BART10 targets the 3′-UTR of BHRF1
to inhibit apoptosis.55 Several EBV miRNAs (miR-BART3,
miR-BART5, miR-BART16, miR-BART17, miR-BART19,
and miR-BART20) have been reported to downregulate latent
membrane protein 1 (LMP1), an EBV integral membrane protein that functions as an oncogene by promoting cell survival
and preventing apoptosis.55–57 Although it is counterintuitive
that EBV miRNAs would negatively regulate LMP1, high
levels of LMP1 can actually promote apoptosis,58 and so tight
control of the gene is necessary. It is also of interest to note
that BZLF1 and BRLF1, two EBV genes associated with the
switch from latency to lytic infection, are not targeted in BL
cell lines by these EBV miRNAs.55 This indicates that these
miRNAs are not directly responsible for regulating the latentlytic switch, unlike HSV-1 and HSV-2 miRNAs.
Also, EBV miRNAs can target host mRNAs to prevent
apoptosis. Gene ontology analysis of the host mRNA targets of the 12 most abundant EBV miRNAs indicated that
132 apoptosis-associated host genes may be targeted by EBV
miRNAs.55 Notably, the p53 upregulated mediator of apoptosis (PUMA), a pro-apoptotic gene induced by p53, has been
shown to be targeted by miR-BART5 and miR-BART19.55,59
30
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Also related to promoting apoptosis, the BCL2 family member BCL2L11 (BIM) is targeted by miR-BART4 and miRBART15,60 and possibly several miRNAs together,61 to
orchestrate the downregulation of this target. EBV-infected
GaCa cell lines exhibited reduced apoptosis due to the interaction of miR-BART4 with BID, another Bcl-2 family member
involved in regulating apoptosis.62 Again, differential expression of these miRNAs may occur depending upon the type of
cell (B cell versus epithelial cell) or latency program.47
EBV miRNAs have also been implicated in evasion of
NK cells through miR-BART2-mediated downregulation of
MHC Class I Polypeptide-Related Sequence B (MICB), a
stress-induced NK cell ligand, in epithelial cell lines.55,63 In
addition, the T cell-attracting chemokine CXCL11, produced
by B cells during EBV infection, is downregulated by EBV
miR-BHRF1-3.12,64 EBV miR-BART18 decreases the histone acetylase cyclic AMP-responsive element-binding protein
(CBP),65 which along with p300 associates with IRF3 and
IRF7 to induce the transcription of Type 1 interferon (IFN)
genes. Blocking miR-BART18 in Akata A.15 cells, an EBV+
BL cell line, led to increased Type 1 IFN signaling, as measured in terms of ISG-15 expression using Northern blot.65 As
Type 1 IFN is important in inducing an antiviral state and
activating NK and T cells, miRNA-mediated downregulation
of the expression of this cytokine would be expected to greatly
benefit the virus. Taken together, this work shows that in addition to preventing apoptosis of infected cells, viral miRNAs
may also function to prevent host immune effects without the
use of immunogenic viral proteins. All herpesviruses still contain a large cohort of protein-encoding genes that interfere
with host immune responses, which raises the question of the
relative in vivo significance of viral miRNAs versus proteins.
Infection of mouse models with homologous miRNA-deficient herpesvirus strains will likely provide important context
within an in vivo system.
The other human gammaherpesvirus is Kaposi’s sarcomaassociated herpesvirus (KSHV) (HHV-8). The greatest risk of
infection with KSHV is for immunocompromised individuals, who more frequently develop Kaposi’s sarcoma. Like EBV,
KSHV infection is also associated with PEL and multicentric
Castleman disease.66

K12 (kaposin)

117,432

v-Flip

v-cyclin

LANA

127,296

miR-K12-12 10 9 8 7 11 6 5 4 3 2 1

Figure 2. Genomic location of KSHV pre-miRNAs. KSHV pre-miRNAs
cluster within the KLAR, which also contains genes for LANA, v-Cyclin,
v-FLIP, and Kaposin. All the miRNAs map to the K12 locus: miR-K12-1
through miR-K12-9 and miR-K12-11 are encoded within the K12 intron,
while miR-K12-10 and miR-K12-12 map to a K12 open reading frame and
the 3′-UTR, respectively.
Note: Figure reprinted from Ref. 81 under a Creative Commons
Attribution License.
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According to miRBase.org, 29 13 pre-miRNAs and
25 miRNAs are found within the KSHV genome. The miRNAs
are all located as a cluster within the KSHV latency-associated
region (KLAR), which encodes four genes expressed during
latency and lytic infection: latency-associated nuclear antigen
(LANA), v-Cyclin, v-FLIP, and Kaposin (K12). All the miRNAs map to the K12 locus: miR-K12-1 through miR-K12-9
and miR-K12-11 are encoded within the K12 intron, while
miR-K12-10 and miR-K12-12 map to a K12 open reading
frame and the 3′-UTR, respectively (Fig. 2).18,67,68 Although
the relative expression levels can vary in different cell types,
the 10 miRNAs encoded on the K12 intron are generally
expressed as a group in latently infected cells.9,69,70 In contrast,
miR-K12-10 and miR-K12-12 are expressed alongside the
K12 gene during lytic infection.71
The cluster of KSHV miRNAs is expressed alongside
the KLAR genes during latency, and similar to HSV-1 and
HSV-2 miRNAs, it has been shown to play a role in preventing reactivation to the lytic cycle. The expression of the KSHV
replication and transcription activator (RTA), the master
regulator of the latent-lytic switch, is negatively regulated by
miR-K12-9 and miR-K12-7.72,73 Similarly, miR-K12-3 and
miR-K12-11 target cellular activators of RTA.74 Inhibiting
or eliminating these KSHV miRNAs (or a cluster including these miRNAs) induced elevated lytic gene expression
and spontaneous lytic reactivation in fibroblasts, endothelial
cells, and PEL cells.72–75 This further emphasizes that several
KSHV miRNAs are involved in the maintenance of latency in
both lymphoid and non-lymphoid cells. It is also interesting
to note that host-encoded miR-498 and miR-320d have also
been shown to target RTA in a PEL cell line,76 and 5 of the
99 cellular miRNAs induced by ectopic expression of HIV nef
have putative binding sites in the 3′-UTR of the RTA gene.77
Recent work by McClure et al and Bai et al mapped the
3′-UTRs of KSHV genes and discovered that these regions
are important in the negative regulation of KSHV genes.78,79
A total of 28 potential KSHV gene targets of known KSHV
miRNAs were identified that correspond to all stages of viral
replication,79 indicating that many miRNA targets have yet to
be investigated.
In addition to viral transcripts, KSHV miRNAs target
many host mRNAs. Notably, KSHV miRNAs are thought to
target .1000 putative host genes,9,70 although not necessarily
directly.80 Several classes of cellular genes consistently targeted
include apoptosis, angiogenesis, cellular metabolism, lymphocyte activation, and immune modulation genes.9,80,81 For example, several KSHV miRNAs target cellular thrombospondin 1,
which is thought to negatively regulate angiogenesis and proliferation.81 KSHV miR-K12-K1 binds the 3′-UTR of CDKN1A
(p21) to inhibit p53-induced cell-cycle arrest in PEL B cells.82
Similar to EBV, MICB is also targeted by miR-K12-K7,
a KSHV miRNA.63 Haecker et al used Ago HITS-CLIP to
identify a collection of cellular pathways targeted by KSHV
miRNAs. Identified genes included 42 involved in apoptosis,

11 in cellular metabolism (glycolysis), 13 in lymphocyte activation (in BCBL-1 cells), and 21 in mitosis (in BC-3 cells).9
This emphasizes that this complex virus is capable of affecting multiple host signaling pathways through the effects of
numerous viral miRNAs.
As a herpesvirus, KSHV encodes several viral orthologs
of host genes, including IL6, CFLAR (FLIP), CCND, and
IRF3. Similarly, the virus also encodes orthologs of host
miRNAs. KSHV expresses miR-K12-11, an ortholog of the
human miR-155, during latent infection.83 Host miR-155 is
involved in the clonal expansion of lymphocytes following
antigenic stimulation,84 and miR-155 transgenic mice have
been shown to develop B cell lymphomas,85 lending support
to the hypothesis that miR-K12-11 may assist in the induction of oncogenic processes within cells. Notably, although
the related gammaherpesvirus EBV does not encode its own
ortholog of miR-155, this cellular miRNA is the most abundant miRNA (of cell or virus origin) induced by EBV infection
of LCLs.86 KSHV miR-K12-10a and miR-K12-3 (including
the SNP-containing miR-K12-3+1) also act as viral orthologs
of cellular miR-142-3p and miR-23, respectively.70,87 The viral
and cellular miRNAs can show mutually exclusive expression
in different cell types; however, miR-23 is highly detected in
endothelial cells, while miR-K12-3 is expressed in PEL cell
lines.87 Similarly, cellular miR-155 is highly expressed in
infected endothelial cells, while miR-K12-11 is expressed in
PEL cell lines.88
In addition to encoding homologs of cellular miRNAs and
its own miRNAs that target host genes, KSHV also expresses
proteins that induce several infection-promoting cellular
miRNAs. For example, knocking down cellular miR-21 and
miR-31 prevented KSHV K15M-mediated motility of PEL
cells,89 and cellular miR-132 regulates interferon-stimulated
genes in KSHV-infected lymphatic endothelial cells.90 It is not
surprising that several herpesviruses use miRNAs to interfere with Type 1 IFN signaling; miR-K12–12 also appears
to target CBP, which is involved in the activation of Type 1
IFN genes.65
Betaherpesvirinae subfamily members: human cytomegalovirus, HHV-6A, HHV-6B, and HHV-7. Human cytomegalovirus (HCMV; officially HHV-5), HHV-6A, HHV-6B, and
HHV7 establish latency in leukocytes and are characterized
by slower replication than the other herpesv iruses. Healthy
individuals generally do not display symptoms when infected
with HCMV, although 10–20% of infectious mononucleosis
cases are attributed to the virus. The virus can reactivate and
cause life-threatening disease in immunocompromised individuals, and HCMV is the most prevalent congenital infection in industrialized countries.
According to miRBase.org, 29 15 pre-miRNAs encode
26 mature HCMV miRNAs. Unlike KSHV or EBV, the
HCMV miRNAs are scattered throughout the viral genome.
They can be found on both strands, present in 3′-UTRs or
within intergenic regions.91
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HCMV miRNAs target both viral and host genes.
Most HCMV miRNAs correlate with the expression of
lytic genes.92,93 miR-UL112-1 targets several HCMV genes,
including IE1, IE72, UL112/113, UL114, and UL120/121.94–96
The expression of UL138, a viral protein that contributes
to latency,97 is decreased 46% in miR-UL36-transfected
HEK293 cells,98 suggesting that this miRNA may be involved
in maintaining productive infection. However, no HCMV
miRNA has been found to be essential for replication.
Although the majority of its miRNAs have been characterized during lytic infection, HCMV may also encode a
subset of miRNAs that self-regulate to maintain a latent state.
As mentioned above, miR-112-1 has been shown to downregu
late IE72, an abundant HCMV transactivator necessary for
induction of E and L gene expression.95 The HCMV IE1 and
IE2 transactivators are central to reactivation from latency,99
and HCMV miR-112-1 binds to the 3′-UTR of IE1 and
reduces reporter expression in transient-transfection assays of
HEK293T cells.96 In support of this, miR-US33 transfection
of human embryo lung fibroblast cells reduced infectious viral
titers and IE1/IE2 proteins at a multiplicity of infection of
0.01 (although not 0.1, 1, or 5).93 Thus, although few HCMV
miRNAs are found to be expressed during latency, several
putative miRNAs may have a significant effect upon the suppression of required IE genes.
In addition to targeting viral genes, HCMV also
encodes miRNAs that target cellular genes. For example,
miR-US25-1 and miR-US25-2 target several cellular targets,
many of which are associated with cell-cycle control, and
infection with an miR-US25-1 knockout virus resulted in
increased cyclin E2 expression in human primary fibroblast cells.100 Like other herpesvirus miRNAs, HCMV also
encodes miRNAs that target cellular genes in an effort to
evade host immune responses. Notably, HCMV miR-UL112
was the first miRNA shown to inhibit expression of MICB.
It also acts in concert with the HCMV-encoded UL16 protein to inhibit expression of MICB when UL16 protein levels are reduced.101 CCL5, a chemokine that attracts T cells,
is downregulated in human foreskin fibroblasts by HCMV
miR-UL148D,102 while MHC Class I peptide loading is
inhibited by the miR-US4-1-mediated downregulation of
endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1).103
Taken together, HCMV encodes several miRNAs that function to regulate host responses.
Whereas HHV-6A is an orphan virus, HHV-6B and
HHV-7 cause roseola infantum and are associated with febrile
seizures of children below two years of age. Deep sequencing has identified four miRNAs, termed hhv6b-miR-Ro6-1
through miR-Ro6-4, encoded within the left and right direct
repeat regions of HHV-6B.104 Hhv6b-miR-Ro6-3, miRRo6-2, and miR-Ro6-1 are antisense to the predicted B1, B2,
and B3 open reading frames (ORFs), respectively, that are
thought to encode IE genes.105 Future studies will determine
if these HHV-6 miRNAs are involved in regulating early lytic
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infection or maintaining latency. Thus far, no viral miRNAs
have been identified for HHV-7.
Biomarker and therapeutic potential with respect to herpesvirus miRNAs. Herpesviruses encode proteins that subvert
host immune responses, and it is clear that the viruses also
encode several miRNAs that interfere with innate and adaptive antiviral mechanisms. Type 1 IFN signaling activates a
variety of cellular antiviral pathways and is a potent inducer
of NK cell activation and cytotoxicity.106 Not surprisingly,
HCMV, EBV, and KSHV encode miRNAs that target Type 1
IFN signaling,65 and these viruses also encode miRNAs
that downregulate MICB.55,63,101 Blocking miR-BART18 in
an EBV+ BL cell line resulted in increased Type 1 IFN
signaling,65 highlighting that efforts to inhibit herpesvirus
miRNAs could be fruitful in reestablishing IFN-induced
antiviral pathways. Likewise, inhibition of viral miRNAs may
be useful to reverse IFN refractoriness of EBV+ or KSHV+
tumor cells65 or increase the efficacy of interferon therapy for
herpesvirus conditions, such as HSV epithelial keratitis.107
Conversely, these herpesvirus miRNAs could assist in the
regulation of aberrant Type 1 IFN responses in systemic lupus
erythematosus and other diseases.108
Adaptive immune responses are also circumvented
through herpesvirus miRNAs, either directly or indirectly.
Inhibition of Type 1 IFN signaling through miRNAs mentioned above can negatively regulate antigen-presenting cell
(APC) and CD8 T cell responses.109,110 In addition, T cellattracting chemokines CXCL11 and CCL5 are targeted by
EBV and HCMV miRNAs, respectively,12,64,102 and HCMV
miR-US4-1 downregulates ERAP1 to inhibit MHC Class I
peptide loading in the ER.103 Correspondingly, inhibition of
herpesvirus miRNAs during infection would be expected to
modulate APC and T cell responses.
Herpesvirus miRNAs have huge potential as biomarkers
of diagnosis and disease progression. As an example, HCMV
is the most common infection of patients after organ transplantation and can drastically affect morbidity, mortality, and
organ rejection. Diagnostic results assist in monitoring of
infection following transplantation and guide decisions to give
preemptive therapy.111 The current standards to test for acute
infection include serology for IgM/IgG titers, an antigenemia assay to test for HCMV pp65 antigen, and quantitative
nucleic acid testing (QNAT) using PCR. However, falsepositive serology results can occur in patients with EBV or
HHV-6 infections, and IgM antibodies take weeks to appear.
This underscores the limitations of traditional serology to
quickly assess new infection. Moreover, the pp65 antigene
mia assay cannot be used in patients with neutropenia, and
QNAT is extremely sensitive and faster than culture but does
not differentiate between shedding of virus in the absence
of active disease.111 Certain HMCV miRNAs are expressed
at different stages of viral replication and could therefore be
used to further monitor primary infection or reactivation from
latency. Samples could be easily obtained from biopsies, whole
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blood or plasma, known areas of shedding such as saliva, or
other fluids such as cerebrospinal fluid. In support of using
herpesvirus miRNAs as biomarkers, Kawano et al found that
certain EBV miRNAs were elevated in plasma of patients with
chronic active EBV infection compared to control patients or
patients with infectious mononucleosis.112 A recent study by
Zhang et al found that EBV miR-BART7 and miR-BART13
levels in plasma specimens produce a 90% predictive value for
NPC. In addition, both miRNAs were downregulated following radiotherapy.113
Exosomes, which are lipid microvesicles released from
cells, are thought to provide extra stability to their encapsulated
miRNAs. Exosome miRNA can be separated from free
miRNAs, virion-associated miRNAs, or genomic nucleic
acid.114 miRNAs have been detected within exosomes in
plasma from human patients with KSHV and from EBV+
LCL and NPC cell lines.69,114–116 Exosome-associated miRNAs in plasma could provide more stable samples for analysis, leading to better diagnostics to monitor active infection or
herpesvirus-associated malignancies.
Although some herpesviruses exhibit conservation in
their miRNA seed regions, diagnostic miRNA microarrays
could provide a means to differentiate between herpesvirus
infections that cause similar conditions, such as roseola infantum caused by HHV-6B or HHV-7. The plausibility of this
idea is supported by a study by Marshall et al that showed
that the majority of KSHV-encoded miRNAs were highly
conserved within clinical isolates.69 Because reactivation from
latency is a critical step in the replication of herpesviruses,
comparison of lytic versus latent miRNAs may also be useful
in diagnosis, monitoring, and treatment. Although excellent
work has been done to elucidate the biological functions of
the miRNAs present during herpesvirus infection, additional
serum profiling studies from infected individuals need to be
performed in order to have a more thorough understanding of
which viral and cellular miRNAs are present during the different stages of herpesvirus infection.
Polyomaviruses. Another family of double-stranded
DNA viruses that replicate in the nucleus is the Polyomaviridae. The family is divided into three genera, two of which
infect mammalian hosts while the third infects avian hosts.
A curiosity of the polyomaviruses lies in the fact that humans
exhibit subclinical persistent infection at very high rates in the
population, with primary infection occurring at a young age.
It is unclear whether or not there is a true latent stage, but

asymptomatic individuals routinely shed polyomavirus particles in their blood and urine.
Infections of humans with polyomaviruses can result in
serious diseases, although it is usually quite rare. For example, infection with Merkel cell polyomavirus (MCPyV)
can lead to Merkel cell carcinoma117 and BK polyomavirus
(BKPyV) can cause polyomavirus allograft nephritis, polyomavirus hemorrhagic cystitis, and bladder cancer in some
cases.118–125 Additionally, JC polyomavirus (JCPyV) can cause
progressive multifocal leukoencephalopathy (PML) and has
been associated with cases of colorectal cancer,126,127 while
trichodysplasia spinulosa-associated polyomavirus can cause
trichodysplasia.128
As nuclear DNA viruses, polyomaviruses are good candidates to encode miRNAs. Unlike the herpesviruses that
each encodes a handful of miRNAs, most or all polyomaviruses encode a single pre-miRNA within the large T antigen (LTAg) gene (Table 3). Although the exact location of
the pre-miRNA varies, it is always oriented in the opposite
direction of the LTAg and is transcribed as part of late transcription events. Two mature miRNAs are produced from the
pre-miRNA that downregulate the expression of the LTAg,
which is necessary for the early/middle phase of the infection
cycle. Therefore, the main role of the polyomavirus miRNAs
appears to be in helping the transition from the early to late
phase of the infection cycle.
Cellular targets of polyomavirus miRNAs have also
been identified and appear to target immune responses. Both
JCPyV and BKPyV miRNAs bind to the 3′-UTR and reduce
translation of UL16-binding protein 3 (ULBP3) mRNA,
a stress-induced ligand of NK cells, in an effort to evade an
NK response against the virus.129,130 Cytotoxic T cell responses
against SV40, specifically cell lysis and IFN-γ production, are
reduced indirectly through viral miRNA-induced downregulation of LTAg and small T antigen.131 Other host targets
have been predicted in SV40 and MCPyV, but are yet to be
shown experimentally.132,133
The 5′ and 3′ miRNAs encoded by polyomaviruses
appear to have potential as biomarkers of infection and are
detectable in plasma, urine, brain tissue, colon tissue, and
feces.134–136 JCPyV miRNA was isolated from both plasma
and urine in healthy asymptomatic individuals using qRTPCR, which was more sensitive in detecting the presence
of the virus than traditional serological methods.136 JCPyV
miRNA has been found in postmortem brain tissues of PML

Table 3. Summary of human polyomavirus-encoded miRNAs.
Virus

miRNA

miRBase no.

Genomic
position

Target

References

JCPyV

jcv-mir-J1

MI0009980

3’ end of LTAg

LTAg, ULBP3

130,134

BKPyV

bkv-mir-B1

MI0009981

3’ end of LTAg

LTAg, ULBP3

130,134

MCPyV

mcv-mir-M1

MI0010647

Middle of LTAg

LTAg

133,138
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patients,134 and miR-J1-5p was also detectable in colon tissue
and feces of healthy subjects.135 Interestingly, miRNA expression was lower in diseased versus normal adjacent tissue and
inversely correlated with expression of LTAg, possibly supporting its role in downregulating expression of the protein.135
Currently, serology for JCV proteins is most commonly used to
indicate infection, but together with the apparent stability of
the miRNA,134 the ease in obtaining polyomavirus miRNAs
from patient samples indicates that they may be powerful biomarkers for detecting asymptomatic forms of polyomavirus
infections. On the other hand, using host-encoded miRNAs
that are induced by PyV infection as potential biomarkers may
not be as fruitful: in a miRNA profiling study, Lagatie et al
found that there was no significant difference in host-encoded
miRNAs between individuals with or without JCPyV.137
Using polyomavirus miRNAs or their respective
antagomirs (complementary oligonucleotides used to silence
miRNAs) as therapeutics will most likely be difficult. A major
problem lies in the fact that most individuals are infected
asymptomatically by PyVs and never develop serious health
consequences. Later, when the virus is assumed to be in a
latent form of infection, the miRNA is not being expressed
and thus there is no target to antagonize. In cases where tumorigenesis has occurred and a proviral form exists, the virus is
likely to be expressing only E genes,138 which does not include
the miRNA. Since tumorigenic activity is believed to largely
come from the action of LTAg,139 it is interesting to speculate that the PyV miRNA could serve as a therapeutic in
malignant cells to theoretically reduce the amount of LTAg
expressed. However, this is also likely to induce the lytic cycle,
which may have its own unintended consequences.
Hepatitis B virus. The hepatitis B virus (HBV) is a
small, enveloped DNA virus belonging to the Hepadnaviridae family. The primary cellular target of infection by HBV is
human hepatocytes. It is estimated that as many as 400 million
people may be chronically infected worldwide140,141 with up
to 1 million annual deaths, as a result. Not only can chronic
HBV infection lead to hepatitis or cirrhosis but also is the
cause of up to 80% of the cases of hepatocellular carcinoma
(HCC), the fifth most commonly diagnosed cancer and the
second most common cause of cancer death in the world.142
As a DNA virus that enters the nucleus, HBV is a good
candidate to encode miRNAs. Nevertheless, no HBV miRNAs
have been verified experimentally, and only one has been identified through computational methods.143 On the other hand,
there are a large number of host-encoded miRNAs described
that interact with HBV and are differentially expressed during the course of infection (Table 4). Additionally, miRNAs
have been identified that are specifically involved in the progression of HBV-related diseases.144 Thus, cellular miRNAs,
rather than viral miRNAs, may have the potential to become
powerful biomarkers of HBV pathology.
The most studied miRNA involved in the course of HBV
infection is perhaps miR-122. It represents 50–70% of the
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miRNAs found in normal liver cells145–147 and plays a role in
maintaining homeostasis, as well as regulating metabolic pathways involving lipid and cholesterol metabolism.148,149 miR-122
has been shown to downregulate cyclin G1 and heme oxygenase
1 (HMOX1), resulting in inhibition of HBV replication.150–152
Additionally, Chen et al found that miR-122 has viral mRNA
target sequences located in the HBV coding region of the reverse
transcriptase and the 3′-UTR of the HBcAg core protein.153
The virus counters with production of X protein, which binds
peroxisome proliferator-activated receptor gamma to inhibit the
transcription of miR-122.154 In addition, all four HBV mRNAs
have complementary sites for miR-122 that act as sponges to
sequester endogenous copies of the miRNA.155
Not surprisingly, miR-122 is downregulated in a number of
HBV-associated hepatic cancers.156 Fan et al showed that miR122 negatively regulates tumor-promoting N-myc downstreamregulated gene 3, which is upregulated in HCC+ patient liver
samples compared to normal adjacent tissue.157 The biological importance of miR-122 was further emphasized when the
malignant phenotype of an HBV-related HCC cell line could
be reversed by transient transfection of miR-122 into the cells.157
Inhibition of miR-122 also leads to the increased expression of
pituitary tumor transforming gene binding factor, resulting in
liver cancer cell proliferation, invasion, and tumor growth.158
Other cellular miRNAs are targeted in a similar manner by HBV. Two well-known tumor suppressor miRNAs,
miR-15a and miR-16-1, are found in multiple human cancers and are decreased in HBV-infected cells by HBV X protein.159–161 As occurs with miR-122, HBV mRNAs have a site
complementary to miR-15a and miR-16-1 and act as sponges
to sequester the miRNAs. As a result, the oncogene Bcl-2,
a regulatory target of miR-15a/16-1, was increased significantly in HBV-transfected cells.162 Viral targeting of these
miRNAs, specifically miR-15a, likely evolved in response
to the ability of the host miRNA to target HBp and HBx
transcripts to suppress HBV infection.159
Several other cellular miRNAs are induced by infection, although not all result in a benefit to the host. HBsAg
expression and HBV proliferation are directly suppressed by
miR-199a-3p and miR-210,163 and miR-125a-5p downregulates
the expression of HBsAg.164 On the other hand, Zhang et al
showed that miR-1 indirectly enhances HBV replication by targeting histone deacetylase 4 and E2F transcription factor 5, the
activation of which arrests the cell cycle and reverses the cancer
phenotype.165 In support of this, it has been found that miR-1
is epigenetically regulated and found in lower levels in HCC
cells.166 Paradoxically, the HBV HBx protein promotes the
expression of cellular miR-148a, which enhances tumorigenesis
and promotes cell proliferation, cell migration, and anchorageindependent growth of HepG2 and Hep3B cells.167,168 Further
research is needed to discern the relationship between tumorigenic and antitumorigenic miRNAs during HBV infection.
Traditional detection methods and notable miRNA biomarkers of HBV infection. Alanine aminotransferase (ALT) and
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Table 4. Host miRNAs involved in HBV-related health conditions.
miRNA

Target

Effect

References

miR-1

FXRA, HDAC4, MET

Increase HBV transcription

165,166

miR-15a/16

HBV RNA, BCL2, CCND1 (host), NCOR2

HBV RNA is sponged; prevents apoptosis

159,161,162,364

miR-17/92 cluster

HBV RNA, E2F1, E2F3

Promotes HCC proliferation

365,366

miR-18a

ESR1

Promotes HCC proliferation

367

miR-21

PTEN, PDCD4

miR-22

HDAC4, ESR1, CDKN1 A

miR-23b

PLAU, MET

373

miR-26a

ESR1, IL6, CCND2, CCNE2

374,375

miR-29a

PTEN

376

miR-29c

TNFAIP3

Tumor suppressor

377

miR-34a

CCL22, MET

Inhibits HBV

378

miR-99a

IGF1R, MTOR

379

miR-101

DNMT3A, FOS, MCL1, EZH2

380–384

miR-122

CCNG1, HMOX1, HBV mRNA

Inhibits HBV replication and translation;
increased HBV core stability

153,154,156,160,161

miR-125a-5p

HBV S gene, ERBB2

Reduced expression of HBsAg; inhibits cell
proliferation

164,385–387

miR-141

PPARA

Inhibits HBV replication

388

miR-143

FNDC3B

389

miR-145

HDAC2, ADAM17

390,391

miR-146a

STAT1

Promotes HBV infection

392

miR-148a

DNMT1, HPIP, MET

Loss of repression of HBV transcription

168,240,393

miR-152

DNMT1

Loss of repression of HBV transcription

240,394

miR-155

CEBPB, SOCS1, SOX6

Decreases HBV transcription; increases host
immune response

395,396

miR-199-3p

PAK4, MTOR, MET, HBsAg mRNA

Inhibits HBV replication

163,397–399

miR-199a

HBV S region

Inhibits HBV replication

163

miR-205

HBx mRNA

Inhibits HBV

400

miR-210

AIFM3, HBsAg mRNA, HBV Pre-S1 region

Reduces HBsAg; inhibits HBV replication

163

miR-222

PPP2R2 A

miR-224

API5, ARHGAP9, ARHGAP12, SMAD4

Inhibits apoptosis; promotes metastasis

402–404

miR-372

PRKACB, NF1B

Decreases HBV transcription; increases HBV
expression

405,406

miR-501

HBXIP

Promotes HBV replication

407

miR-548

IFNL1

Promotes HBV infection

408

miR-602

RASSF1 A

Oncogenic

409

let-7 family

STAT3, COL1A2, MYC, NGF, BCL2L1,
RAS, HMGA2

Increases cell proliferation

364,410,411

aspartate aminotransferase (AST) are the most commonly
used biomarkers to assess liver damage,169 although levels
can be altered through conditions unrelated to the liver.170,171
A more definitive diagnosis can be obtained by liver biopsy,
but biopsy is costly, inconvenient, and may not be accessible
to all individuals.172 Furthermore, complications such as pain,
mental and physical anguish, bleeding, and even death are
possible.172–174 Another problem with liver biopsy lies in the

366,368,369
Inhibits HBV replication

370–372

401

sampling nature of the biopsy itself. Typically, liver samples
taken at biopsy represent 1/50,000th of the total liver, which
could result in random sampling error.172 While ultrasound
is a tempting noninvasive alternative and good for assessing
late stage liver damage, it is not very useful in assessing earlier
stages of disease.175
For specifically identifying HBV as a causative agent of
liver damage, current serological methods consist of antibody
Biomarker Insights 2015:10(S4)
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Table 5. Host miRNAs reported to be differentially expressed in
serum/plasma during HBV infection.
miRNA upregulated

miRNA down
regulated

References

miR-10a, miR-23a/b, miR-99a, miR-15a, miR-16-1, 177,178,180,
miR-122, miR-150, miR-223,
miR-21, miR-744
182,183,
miR-342-3p, miR-375, miR-423,
412–414
miR-572, miR-575, miR-638

tests for HBsAg and HBeAg antigens. PCR assays may also
be used for direct determination of HBV genomic DNA in
serum. For identification of HBV in tissues, detection of
HBsAg and HBcAg by immunohistochemical staining or
HBV DNA by Southern hybridization, in situ hybridization,
or PCR is performed.176
Considering the above challenges, miRNAs have
emerged as an alternative biomarker method with the possibility of monitoring the progression of disease in individuals.
Multiple studies have already shown that noninvasive testing for miRNAs has the potential to be used as biomarkers
of HBV infection and HBV-positive HCC.177,178 A number
of specific, differentially expressed host miRNAs have been
identified in the last decade; a partial list is shown in Table 5.
One of the most widely used miRNA biomarkers for
HBV is miR-122, not surprising due to it being one of the most
thoroughly studied miRNAs in HBV infection and liver disease. Waidmann et al found that the serum levels of miR-122
were effective as a biomarker in HBV-infected patients as they
discriminated infected from healthy subjects, discriminated
inactive carrier patients with high or low levels of HBsAg,
and correlated with the levels of ALT, HBV genomic DNA,
and HBsAg.179 It has also been shown that both miR-122 and
miR-18a are released in the blood and could be used for HBVrelated HCC screening.160,179,180 An miRNA profiling study
on HBV and hepatitis C virus (HCV) found that miR-122
was significantly upregulated in serum of patients with both
viruses, whereas elevated miR-22, miR-99, and miR-125b
levels were more characteristic of chronic HBV infection and
may be useful in discriminating between infection with the
two viruses.181
Other panels of miRNAs have also been found to be
differentially expressed between healthy and chronic HBV
patients. Zhang et al identified 34 miRNAs dysregulated
in chronic hepatitis B patients, with miR-122, miR-572,
miR-575, and miR-638 upregulated and miR-744 downregulated significantly.182 A study examining miRNAs in the
plasma of chronically infected children identified 16 miRNAs
to be upregulated in HBeAg+ compared to children with
HBeAg−: miR-99a, miR-100, miR-122, miR-122*, miR-125b,
miR-192, miR-192*, miR-193b, miR-194, miR-215, miR-365,
miR-455-5p, miR-455-3p, miR-483-3p, miR-885-5p,
and miR-1247.183 Another miRNA serum profiling study
also identified miR-99a-5p, miR-122-5p, and miR-192-5p as
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significantly overexpressed between chronic hepatitis B adult
patients and inactive carriers. Using an MiR-B-Index that
normalized these three miRNAs to internal control miRNAs
(miR-126, miR-320a, and miR-335), the same study showed
that the serum miRNA profile of patients responding to pegylated (PEG)-IFN alpha resembled that of inactive carriers,
while nonresponders and relapsers matched baseline measurements of patients with chronic hepatitis B.184 This comprehensive study illustrated that miRNAs could be useful not only
in assessing disease status (inactive carriers vs. chronic hepatitis B patients) but also in identifying responders to certain
treatments, such as PEG-IFN. The study also emphasized
that although a single biomarker is desirable for simplicity
and financial reasons, panels of biomarkers can also be effective in determining disease state and response to treatment.
Further support for biomarker panels is provided by several
studies.177,185,186 Notably, Li et al used a panel of 13 miRNAs
to distinguish control patients from those with HBV infection
(miR-10a, miR-223, miR-375, and miR-423), control patients
from those with HBV-HCC (miR-23a, miR-23b, miR-92a,
miR-342-3p, miR-375, and miR-423), patients with HBV
from those with HCV infection (miR-92a up in HCV and
miR-375 up in HBV), and patients with chronic HBV from
those with HBV-positive HCC (miR-19a and miR-125b).177
Liver injury can produce similar biomarker responses,
regardless of the causative agent. An interesting miRNA
profiling study by Ura et al examined the expression of 188
miRNAs from HBV-HCC, HCV-HCC, and normal patients.
They identified 19 miRNAs that were differentially expressed
between HBV and HCV.187 In all, 31 miRNAs were associated
with liver disease, regardless of the virus, but 6 were specific
for HBV and 13 for HCV. Notably, miR-105, miR-134, and
miR-211 were over fourfold upregulated in HBV and miR34c was over fourfold increased in HCV.187 However, other
studies have produced conflicting results,188,189 and thus, the
miRNAs identified are likely to need further validation.
Role of miRNAs as therapeutics against HBV. The potential
that miRNAs hold to serve as therapeutic agents against HBV
has long been recognized,190–193 and a number of studies have
attempted to employ miRNA to combat HBV in vivo. The
first in vivo result of antiviral RNAi activity used short hairpin
RNAs (shRNAs), essentially, the pre-miRNA hairpin structure, in a study that targeted a mouse model of HBV infection
using hydrodynamic delivery of HBV gene and shRNA vectors.194 Several other early studies also demonstrated inhibition
of HBV by RNAi.195–201 The use of 2′-OH-modified siRNAs
was another approach that enhanced stability and inhibited
infection in an in vivo mouse model of HBV replication.202,203
shRNAs were utilized in early studies, 204–209 but the RNA
polymerase III-delivery method commonly used presented
toxicity problems to the host.210 Thus, modified RNA polymerase II-dependent systems encoding pri-miRNAs were
used that were expressed at lower levels due to the requirement
for Drosha cleavage. These were not toxic and did not interfere
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with the endogenous miRNA production necessary for proper
cell function.201,211–214
Multimeric miRNA expression cassettes have been used
to effectively target multiple sites within the virus genome
using mouse models of HBV infection, 214 and a common
delivery method for the miRNA therapeutic uses adenoassociated virus (AAV) or lentivirus systems.215,216 AAVdelivered miR-26a resulted in cell-cycle arrest in vitro through
direct targeting of cyclins D2 and E2 in HCC cells. In addition, systemic intravenous administration of the AAV-miR26a led to reduced HCC cell proliferation and tumor-specific
apoptosis.217 In an HBV-HCC model, tumor growth was
significantly decreased after lentiviral transduction of miRNA
targeting HBsAg into HBV+ HepG2.2.15 cells before injection into nude mice.218 These and other experiments provide
proof of concept that miRNAs downregulated in cancers
could be reconstituted to normal levels to reduce tumor growth
and that viral genes involved in tumor progression could be
targeted by engineered miRNAs.
Hepatitis C virus. The HCV is a small, enveloped,
positive-strand RNA virus belonging to the Flaviviridae family.
There are an estimated 170 million people infected worldwide,
with up to 500,000 deaths annually as a result. The primary
tropism of the virus is for human hepatocytes. Approximately
80% of those initially infected are asymptomatic, but only
15–25% of initial infections are cleared by the host immune

system. The remainder results in chronic infections, 15–30% of
which will eventually progress to cirrhosis in ∼20 years. HCV
chronic infection is also a significant cause of HCC.142
As a cytoplasmic RNA virus, HCV is unable to encode
miRNAs using traditional nuclear processing machinery,
and no HCV-encoded miRNAs have yet been described.
Additionally, encoding a miRNA within its genome would
be a risky strategy for an RNA virus, as the miRNA processing cell machinery might target the genome for cleavage.
HCV does encode suppressor of RNAi silencing proteins via
the HCV core protein and envelope protein E2, 219,220 and a
plethora of host-encoded miRNAs have been described that
interact with HCV and are differentially expressed during
the course of an infection. In fact, as the disease progresses
from initial infection all the way to HCC, corresponding
changes in miRNA levels have been detected in profiling
studies.187–189,221–223 If a reproducible pattern of specific host
miRNAs could be documented as disease progression occurs,
it could identify miRNAs as powerful biomarkers of HCV
pathology. Table 6 provides a partial list of miRNAs shown
to be differentially expressed or found to interact with HCV
during infection.
Like HBV, most of the attention regarding miRNAs and
HCV has centered around miR-122, which, as mentioned
above, represents 50–70% of the miRNAs found in normal
liver cells.145–147 It is important to note that while miR-122

Table 6. miRNAs involved in HCV infection.
miRNA

Target

Effect

References

miR-21

SMAD7

Increases fibrogenesis

415

miR-26a

CCND2, CCNE2

Inhibits cell proliferation

217

miR-27a

RXRA, ABCA1

Reduces production of HCV virions

416

miR-29

Unknown

Loss leads to fibrosis

417

miR-30d

GNAI1

Promotes metastasis

418

miR-101

MCL1, FOS

Promotes apoptosis

383

miR-122

5’ UTR of HCV genome, XRN1, AGO2,
CCNG1, SOCS3 promoter, ADAM17

Promotes replication, protects HCV 5’ UTR,
stabilizes HCV 5’ UTR, promotes HCV
replication, inhibits metastasis

155,225,226,228,229,419–421

miR-124

ROCK2, EZH2, SMYD3

Tumor suppressor

422,423

miR-130a

IFITM1

Increases HCV replication

424

miR-139

ROCK2

Inhibits metastasis

425

miR-141

DLC1

Increases HCV replication

256

miR-155

APC

Promotes proliferation and tumorigenesis

426

miR-194

CD81

Inhibits HCV entry

427

miR-196 family

HCV NS5A, BACH1

Inhibits HCV replication and RNA/protein
expression

237,238

miR-199a

HCV 5’ UTR IRES

Inhibits HCV replication

236

miR-221

CDKN1B, CDKN1C, BMF

Promotes cell proliferation, inhibits apoptosis

428,429

miR-448

HCV core region

Inhibits HCV replication

238

miR-449a

NOTCH1

Promotes inflammation

430

let-7b

HCV NS5B and 5’ UTR

Inhibits HCV infection

431

let-7g

MYC, CDKN2A, COL1A2

Inhibits proliferation, suppresses metastasis

410, 432
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Table 7. Host miRNAs upregulated during HCV infection.
Compartment

miRNA upregulated

References

Serum

miR-20a, miR-92a, miR-122, miR-134a, miR-320c, miR-483-5p

181,433,434

Infected cell lines

miR-192, miR-193b, miR-194, miR-215, miR-585, miR-768-5p

222,435,436

is an inhibitor of infection by HBV,150,151,153,157 it aids in the
infection of host hepatocytes by HCV. During HCV infection, miR-122 is upregulated and protects the HCV genome
by binding to and masking the 5′-UTR, protecting it from
degradation, and promoting overall replication.224–226 While
bound to the HCV 5′-UTR, miR-122 can also recruit Ago2 to
its 5′ end, which further stabilizes the genome and stimulates
translation of HCV proteins.227–229 Furthermore, miR-122
protects the 5′ end from degradation by Xrn1 exonuclease.155
The net result is an increase in HCV replication and trans
lation of HCV proteins.
Traditional detection methods and putative biomarkers of
HCV infection. The initial testing for HCV is usually done
by enzyme immunoassay to detect host antibodies directed
against HCV.230 Liver damage associated with HCV is also
screened for using ALT and AST enzyme tests. 230,231 Positive
results in initial screenings are usually confirmed via mole
cular testing to detect the presence of HCV RNA, sometimes
followed by patient biopsy to assess the extent of liver damage,
if necessary.230 As described above for HBV, liver biopsies are
not without serious drawbacks.173,174
Algorithms are also used that include a variety of additional criteria and biomarkers such as age, sex, levels of other
liver enzymes, or platelet numbers. Examples include FirboTest and HepaScore.232,233 Unfortunately, many results fall in
the indeterminate category or do not represent liver-specific
injury. Several studies have suggested that miRNAs may
be of great utility in differentiating liver diseases, and one
study in particular showed miRNAs to be more discriminating than AST/ALT while differentiating between liver and
muscle injury.234
Compared to standard diagnostic methods, the potential advantages of using miRNAs as HCV biomarkers include
the noninvasive nature of retrieval, generation of fairly rapid
results, and possible lower costs compared to other methods.
Profiling studies are often used as the first step in identifying
candidate miRNAs that could serve as biomarkers, and there
are already several studies that compare HCV-related disease

states and healthy individuals.187–189,221–223,235 These studies
have begun to reveal the potential of miRNAs to be a useful
tool for diagnosing HCV-related disease as well as monitoring
the progression or regression of the disease.
Several miRNAs are differentially regulated as a result of
HCV or HCV-induced conditions (Tables 7 and 8). Notably,
studies have demonstrated the utility of using miR-122 to
identify HCV, HCC, and hepatocyte injury,181,234 and this
miRNA is also extensively used to identify HBV status.160,177,179
Other host miRNAs directly target HCV genomic sequences:
miR-199a reduces HCV replication by targeting the 5′-UTR
of the genome internal ribosome entry site (IRES) region. 236
Additionally, the expression of miRNA-196b appears to be
upregulated by the IFN pathway and can thus inhibit HCV
by directly targeting NS5A or by indirectly targeting BACH1
and HMOX1.237–239 However, there have been conflicting
results reporting whether it is upregulated or downregulated
during infection, 239–241 possibly making its implementation as
a biomarker difficult. As a way of effectively distinguishing
HCV versus HBV infection, miR-92a and miR-375 are more
highly upregulated in HCV+ or HBV+ patients, respectively.
miR-10a and miR-125b are not upregulated in HCV+ but
highly upregulated in HBV+ individuals,177 although miR-10a
is upregulated in HCV-HCC cases. 223 Several biomarkers
overlap in these and other non-viral liver conditions, emphasizing the importance of biomarker panels to properly differentiate these diseases.
miRNAs as therapeutics for HCV. Current therapeutics
for HCV include the use of PEG-IFN and ribavirin, 242–244
and more recently, sofosbuvir, ledipasvir, and boceprevir have
been used effectively.245–248 While many therapies are successful, there are still a significant number of patients in whom
the virus is not fully cleared.249,250 Additionally, therapies are
costly, not easily accessible to all infected individuals, and can
have severe side effects.251,252
Recently, miR-122 has emerged as a promising candidate in the implementation of miRNAs as therapeutics. The
observation that this abundant liver miRNA is upregulated

Table 8. Host miRNAs differentially expressed in liver tissue biopsies during HCV infection, HCC, or HCV-associated HCC.
Condition

miRNA upregulated

miRNA downregulated

References

HCV

miR-34c, miR-130a, miR-141, miR-155

miR-29, miR-449a

187,256,417,424,426,430

HCC

miR-181, miR-199a, miR-221, miR-301

miR-29, miR-101, miR-139, let-7g

188,383,410,425,429,437,438

HCV-HCC

miR-10a, miR-21, miR-27a, miR-100,
miR-122, miR-155

miR-122, miR-124, miR-145, miR-198

188,223,224,254,364,415,
416,423,426
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and promotes replication during HCV infection made it an
obvious choice to antagonize therapeutically. A small effector
molecule against miR-122 inhibited HCV replication in liver
cells, 253 and Lanford et al used an antisense locked nucleic acid
(LNA; an oligonucleotide with greater strength of binding due
to chemical modification) derivative of miR-122 as a therapeutic in HCV-infected chimpanzees. A sharp reduction in HCV
RNA and improved liver histology was observed without significant side effects or detectable resistance from the virus. 254
Phase 1 clinical trials of miravirsen, an LNA that targets miR122, were completed in 2009 by sponsor Santaris Pharma. In
Phase 2a studies of null responders to PEG-IFN with HCV
genotype 1 infection, miravirsen reduced mean HCV RNA
levels up to three orders of magnitude with no drug-associated
severe or serious adverse events. 255 Notably, HCV RNA levels
increased following cessation of the drug. Long-term admini
stration studies are ongoing (ClinicalTrials.gov identifiers
NCT01727934 and NCT02031133). These results will possibly usher in a new era of miRNA-based biologics.
While the results using miR-122 are promising, there
are still several other miRNAs worth considering to this end.
Pedersen et al described mimics of five miRNAs (miR-196,
miR-296, miR-351, miR-431, and miR-448) that reduced
HCV replication and infection when transfected into HCV+
cells.238 Antagomir-mediated knockdown of miR-141 effectively inhibited HCV replication in infected hepatocytes. 256
Moreover, the mimics of three miRNAs, miR-196b, miR199a-3p, and miR-29, have been expected to function in antiHCV therapy.257
An interesting related approach was considered by Yang
et al who created artificial miRNAs based on five preselected
targets on the HCV genome. When introduced into cells,
they dramatically reduced the replication of cell culturepropagated HCV without causing hepatocellular toxicity. 258

This may suggest that knowledge of the viral target sequence
may be just as valuable, if not more so, than targeting naturally occurring miRNAs. Since artificial miRNAs and their
derivatives are relatively easy to create and introduce into a
host, this could help alleviate the need for extensive profiling
studies to identify aberrantly expressed miRNAs as targets.
Human papillomavirus. HPV is a small, non-enveloped,
double-stranded DNA virus that infects epithelial cells. Over
120 different types have been identified. While most infect
cutaneous epithelium, ∼40 types infect mucosal epithelium,
some of which are associated with oncogenesis. Types 16 and
18 together account for ∼70% of cervical cancer cases. HPV is
also associated with less common cancers, including cancer of
the anus, penis, vulva, and vagina. In the United States, HPV
is the most common sexually transmitted disease. The virus is
also associated with the vast majority of head and neck cancers
in nonsmokers.259
The majority of HPV infections are eventually cleared
from the host, but a small proportion result in persistent infections that can progress to cervical intraepithelial neoplasias
(CINs). High-grade CINs (CIN2 or CIN3) are considered a
precursor to cervical cancer, which may occur within years or
decades.259 As such, much effort has been invested to characterize the role of the virus in oncogenesis, particularly pertaining to the roles of viral oncoproteins E5, E6, and E7.
Recently, host miRNAs have also been implicated in the
process. Several miRNAs have been identified as specifically
targeted by E5, E6, or E7 (Table 9), and their subsequent
cellular effects in many cases have been characterized. E6
targets p53, 260,261 a transcription factor that is thought to be
used for transcription of many cellular miRNAs. 262,263 As
a result, many miRNAs may be drastically underexpressed
and might lead to adverse cellular effects. miR-23b, miR-34a,
miR-203, and miR-218 are all found to be downregulated

Table 9. HPV proteins known to alter host miRNAs.
HPV
Protein

miRNA
target

Effect
(up/down)

Potential cellular effect

References

E5

miR-146a

Up

Suppression of immune response, increased cell proliferation

291

miR-203

Down

Deregulation of p63–increased cell proliferation

291

miR-324-5p

Down

Increased N-Cadherin and E-Cadherin

291

miR-23b

Down

Increase of uPA–induces migration of human cervical cancer cells

264

miR-34a

Down

Increased cell proliferation and transformation

265–267,327

miR-203

Down

Increased cell proliferation

268

miR-218

Down

Deregulation of LAMB3–increased cell migration and tumorigenicity

269

miR-15a/16

Up

pRB degradation, altering c-myb, PPAR, c-myc levels

326

miR-15b

Up

Reduced Cyclin E1–inhibits proliferation

288

miR-203

Down

Blocks MAPK/PKC; increases ∆Np63 activity–increases proliferation

290,439

miR-205

Up

Decreases Akt pathway and Cyclin D1 levels–decreased proliferation

289

miR-21

Up

Targets CCL20–enhances tumorigenesis

440

miR-24

Up

Decreases p27–increases proliferation

289

E6

E6/E7
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in E6-expressing cells, 264–269 which is particularly noteworthy because of the association of these miRNAs with oncogenic processes, in part through direct or indirect effects of
p53 inhibition.
Although all the above miRNAs have been implicated in
cervical cancer, they have also been reported as tumor suppressors in a variety of other cancers: miR-23b in prostate, bladder,
and breast cancers270–272; miR-34a in neuroblastomas, HCC,
and ovarian, colon, pancreatic, and bladder cancers266,273–276;
miR-203 in lung, prostate, and esophageal cancer, as well as
leukemia and glioma 277–279; and miR-218 in prostate, colon,
gastric, and bladder cancer.280–282
E7 degrades the tumor suppressor protein pRB, which
releases E2F from the pRB–E2F complex, 283 freeing E2F to
activate transcription. The promoter regions of several miRNAs
contain E2F binding sites, 280,284,285 which could possibly lead
to adverse effects on the cell if oncogenic miRNAs are transactivated. In contrast to E6-induced miRNAs, most of the miRNAs shown to be dysregulated through the action of E7 are
upregulated, such as miR-15b/16-1, miR-24, and miR-205.286–
289
The downregulation of miR-203 has been credited to the
indirect blocking of the MAPK/PKC pathway by E7.290
Less is known about the actions of E5 on cellular miRNAs. A recent study found that several miRNAs were altered

in HPV16 E5-expressing HaCaT cells.291 Notably, the authors
of that study found that miR-146a was induced, while miR203 and miR-324-5p were repressed. miR-146a and miR-203
had previously been shown to be dysregulated in the same
manner in cervical cancer tissues or HPV+ cell lines.290,292–300
miRNAs as potential biomarkers of HPV infection and progression. It is suspected that the expression of many miRNAs
may be altered during the course of HPV infection, possibly contributing to oncogenesis. Several studies have examined miRNAs dysregulated in cervical cancer or head and
neck squamous cell carcinoma (HNSCC), two cancers that
are likely to be the result of HPV infection. This section of
our review focuses on those fewer studies that specifically
addressed HPV+ cell lines or HPV+ cancer cells/tissues for the
purposes of identifying HPV-specific biomarkers (Table 10),
pointing out when individual miRNAs have also been identified in cancerous cells or tissues with a possible contribution
by HPV.
miR-21 has been implicated as an oncogenic miRNA for
many cancers.301 Indeed, almost all profiling studies to date
of cervical and head and neck cancers have found miR-21 to
be overexpressed in the cancerous state, 292,293,296,300,302–314 and
miR-21 has been shown to be upregulated in HPV-related
cancers as well.308,315 Lajer et al compared HPV+ and HPV−

Table 10. Selected miRNAs identified in HPV-associated conditions.
Change

miRNA

Disease/source

References

Upregulated

miR-15b

HPV+ cervical tissue

286

miR-16

HPV+ cervical tissue

286

miR-21

HPV+ TSCC tissue

315

miR-31

OSCC tissue (HPV±), HPV+ cervical cell lines

269,318

miR-34c

HPV+ cervical cell lines

269

miR-146a

HPV16 E5-transfected keratinocytes

291

miR-181c

HPV+ keratinocytes

441

miR-200c

HPV+ cervical cell lines

269

miR-203

HPV+ cervical cell lines

269

miR-205

HPV+ cervical tissue

286

miR-363

HPV+ HNSCC cell lines, PSCC tissue (HPV±), HPV+ TSCC tissue

315,318,319

miR-497

HPV+ HNSCC cell lines

319

miR-31

HPV+ TSCC tissue

315

miR-34a

HPV+ cell lines, HPV+ cervical tissues

275,326,327

miR-127-3p

PSCC tissue (HPV ±), HPV+ cervical tissue

318,442

miR-143

HPV+ cervical tissue, HPV+ cervical cell lines

269,286

miR-145

HPV+ cervical tissue, HPV+ cervical cell lines

269,286

miR-155

HPV+ HNSCC cell lines

319

miR-181a

HPV+ HNSCC cell lines

319

miR-203

HPV16 E5-, E6-, or E7-transfected keratinocytes

290,291

miR-218

HPV+ cervical cell lines, HPV+ HNSCC cell lines, HPV+ cervical tissue

269,319,442,443

miR-324-5p

HPV16 E5-transfected keratinocytes

291

miR-375

OSCC tissue (HPV±)

318

Downregulated
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patients with tonsillar squamous cell carcinoma (TSCC) and
found miR-21 to be upregulated in HPV+ patients. Additionally, miR-21 was upregulated in HPV+ or HPV− HNSCC as
well as HPV+ cervical squamous cell carcinoma (CSCC), 315
implying that it may serve as an HPV-specific biomarker as
well as a general cancer biomarker. The fact that miR-21 overexpression is detectable in plasma makes it even more appealing as a biomarker.308
Like miR-21, miR-31 is detectable in saliva316 and has
been implicated as an oncogenic miRNA.317 Several oral
cancer tissue profiling studies have found miR-31 to be
upregulated, 293,304,309,310 and it has also been documented to
be upregulated in HPV+ cancers. A study comparing HPV+
oral squamous cell carcinoma (OSCC) patients to HPV− control patients found that miR-31 was the most upregulated
miRNA of OSCC biopsies.318 Interestingly, a follow-up study
by the same group comparing miRNA expression in HPV+
or HPV− TSCC tissue revealed that miR-31 was one of the
most downregulated miRNAs in HPV+ TSCC, 315 further
indicating the potential utility of the miRNA in the differential diagnosis of HPV+ carcinomas.
Other interesting miRNAs were revealed in this study
of HPV+ TSCC, including the upregulation of miR-363
and downregulation of miR-375. In accordance with these
results, miR-363 has also been shown to be upregulated in
both HPV+ and HPV− pharyngeal squamous cell carcinoma
(PSCC) and in HPV16+ HNSCC cell lines.318,319 miR-375
has been found to be significantly downregulated in HNSCC
and OSCC.300,302,311,320
miR-155 is another miRNA that has been found to be
upregulated in several oral cancer profiling studies304,310–312,321;
however, it has been documented as being downregulated
when comparing HPV− and HPV+ cell lines or oral cancer tissues with control tissues.294,319 It is possible that this miRNA
may behave differently in tissue culture as compared to actual
tissue. This was the case for miR-181a, which was found to
be downregulated between HPV− versus HPV+ tissue culture, 319 despite that several profiling studies using cancerous
tissues have identified miR-181a as upregulated. 294,302,304,321
Nonetheless, the consistent appearance of miR-155 in HPVrelated conditions is compelling and worth further investigation.
Similarly, miR-203 has been shown to be upregulated or
downregulated in different studies. miRNA was downregulated
in keratinocyte cell lines expressing HPV oncoproteins, 290,291
which is further supported by several profiling studies that used
tissues from HNSCC or CSCC.294,296–300,306 Martinez et al,
however, found miR-203 to be upregulated when comparing
HPV+ and HPV− keratinocytes.269 Nonetheless, the repeated
appearance of miR-203 in HPV-related conditions warrants
its inclusion in further studies as a potential biomarker. It is
also noteworthy that it has been detected in plasma in patients
with laryngeal squamous cell carcinoma (LSCC).299
Other notably upregulated miRNAs are miR-200c and
miR-205. When 28-fold increased, miR-200c was found to be

the most overexpressed miRNA in HPV16+ cell lines compared to HPV− cell lines.269 miR-205 is known to be induced
via E7 and has been shown to be upregulated in HPV+ cervical cells286 and in several oral cancer profiling studies, as
well.304,322–324 However, one study has indicated that miR-205
is downregulated in HNSCC and is significantly associated
with poor survival.303
In addition to the upregulated miRNAs mentioned
above, several miRNAs have been shown to be downregulated during HPV infection. The expression of miR-143
and miR-145 is reduced in HPV+ cervical cancer cell lines
compared to HPV− cell lines.269,286 Both miRNAs are similarly downregulated in tissues from patients with cervical carcinomas, hypopharyngeal squamous cell carcinoma (HSCC),
LSCC, or HNSCC.297,298,300,304,306,307,311,325 miR-34a is
known to be negatively regulated by the HPV E6 protein, and
its expression was downregulated in HPV16+ cervical cells
and HPV+ cervical tissue.325–327 It has also been shown to be
downregulated in OSCC.294,305
One of the more promising HPV biomarkers may exist in
miR-218, also regulated by the HPV E6 protein. It has been
identified as significantly downregulated in multiple studies
using HPV-infected cells.269,300,319 In fact, a study comparing
HPV+ versus HPV− cervical cancer cell lines found miR-218
to be (the only) significantly underexpressed miRNA.269 It
has been shown to be downregulated in HPV+ squamous cell
carcinoma of the head and neck cell lines and in the HSCC
tissue. Collectively, these studies identify miR-218 as a potential HPV-specific biomarker.
Human immunodeficiency virus. HIV is an enveloped
lentivirus belonging to the Retroviridae family. There is much
controversy concerning whether HIV actually encodes its own
miRNA. As a nuclear RNA virus, HIV might reasonably
avoid encoding miRNAs since Drosha-mediated excision of
a pre-miRNA from the genome could induce the cleavage of
the replicated viral RNA.328,329 Furthermore, it has been suggested that any HIV-1 miRNA would need to play an important evolutionary role in viral replication to compensate for
the degradation of viral genomic RNAs by Drosha cleavage.19
On the other hand, HIV-1 might encode functional miRNAs
because the viral genomic RNA is reverse transcribed in the
cytoplasm into a double-stranded DNA molecule that is
then imported into the nucleus for integration into the host
genome.330 As mentioned above, RNA viruses have been successfully engineered to express functional miRNAs without
reducing viral genome replication. 21 Furthermore, bovine leukemia virus, a retrovirus, avoids Drosha-mediated cleavage of
its genome by encoding miRNAs that are produced by RNA
polymerase III. This creates miRNAs that are too short to be
processed by Drosha/DGCR8 complexes and are instead processed directly by Dicer in the cytoplasm.331
In 2004, five putative HIV miRNAs were computationally identified, 332 and it was later reported that an HIV miRNA
derived from the nef gene, termed miR-N367, targeted the long
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terminal repeat (LTR) U3 region.333,334 However, two reports
subsequently reported that HIV miRNAs – including miRN367 – were not detectable by conventional sequencing of
small RNAs in HIV-infected HeLa cells18 or persistentlyinfected ACH-2 T cells.19 Using in vitro studies, Klase et al
reported that the HIV-1 TAR element, a hairpin structure
∼50 nucleotides in length at the 5′ end of the viral genome,
was processed by Dicer to create viral miRNA that was capable of inhibiting LTR-driven gene expression. This suggested a
post transcriptional silencing method that could contribute to
viral latency.15 Primer extension and RNase protection assays
derived a TAR miRNA duplex that encoded miR-TAR-5p
and miR-TAR-3p,17 and in another study by Klase et al,
HIV-1 miR-TAR-3p/5p was found to protect infected cells
from apoptosis.16 Another HIV-encoded miRNA, miR-H3,
was recently identified through computational prediction and
deep sequencing. Deletion assays suggested that it targeted
the HIV 5′ LTR TATA box to activate viral transcription.335
Deep sequencing studies of HIV-infected T cells identified several HIV small RNAs, including an 18-nucleotide
RNA antisense to the HIV tRNA primer binding site.336
Similarly, Schopman et al used deep sequencing to identify
small RNAs from HIV-infected T cells. One set of small
RNAs originated from secondary hairpin structures formed
by the viral genomic RNA and were attributed as a class of
miRNAs. Although they were found to be in very low proportion in the total small RNAs, three of them were able to prevent luciferase activity when cloned into a reporter construct,
including the previously reported TAR miRNA. Antagomirs
also increased HIV replication of infected 293T cells.337
A recent study by Whisnant et al pointed out that miRNAs
,22 nucleotides are more consistent with RNA breakdown
products than other miRNAs and that a decisive seed region
on the 5′ end of the miRNA must be considered.20 They also
highlighted that low-frequency miRNAs, representing ,0.1%
of the total miRNA pool, are not likely to be biologically relevant.338 They examined small RNAs in two HIV-infected cell
lines, human primary CD4+ peripheral blood mononuclear
cells (PBMCs), and human macrophages, and did not identify any HIV miRNAs.20 By using PAR-CLIP, they found
a small subset of expressed cellular miRNAs that exhibited
complementarity to HIV genome sequences. However, they
determined that these miRNAs are largely unable to interact
with the HIV RNA genome due to extensive viral secondary structures. Since HIV-1 has been implicated in the induction of several cellular miRNAs from infected cells (described
below), this finding generates another layer of controversy in
the matter. Together, these studies emphasize that additional
confirmatory evidence is needed to establish a body of evidence to support or refute whether HIV-1 indeed encodes its
own miRNA.
Cellular miRNAs induced by HIV-1 infection. Studies have
begun to shed light on the involvement of cellular miRNAs
during HIV-1 infection. As mentioned above, additional
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studies will be needed to verify the biological relevance of
these antisense oligonucleotides at the concentrations found
in infected cells. For biomarker discovery, the relative presence or absence of miRNAs (or breakdown products) during
infection is a more important consideration than their absolute concentration, as long as they are consistently detectable
in a validated manner.
During HIV infection, several cellular miRNAs have
been reported to be modulated that indirectly impact the
replication of the virus. In 2007, Triboulet et al used micro
array studies of HIV-infected Jurkat or PBMC to identify 11
cellular miRNAs that were upregulated upon infection and
were dependent upon Drosha and Dicer machinery. Viral
replication occurred faster in the absence of these miRNAs.
Notably, miR-122, miR-297, miR-370, and miR-373* were
only expressed in HIV+ cells, while the miR-17/92 cluster
(that includes miR-17-5p/3p, miR-18, miR-19a, miR-19b-1,
miR-20a, and miR-92-1) was downregulated.339
A challenge of using PBMCs to examine HIV-associated
cellular miRNAs is that miRNAs are expressed differently in
the various peripheral blood cells in the context of different
environments. In an attempt to address this concern, Chang
et al infected the CD4+ SUP-T1 T cell line with HIV-1 or
UV-inactivated HIV-1 and used deep sequencing to identify miRNAs. At 24 hours post infection, 65 and 39 cellular
miRNAs were upregulated or downregulated, respectively, in
the HIV-1-infected cells.340 Similarly, HIV-1 infection of the
CEMx174 hybrid B/T cell line resulted in the increased or
decreased expression of 72 and 106 miRNAs, respectively, as
assessed by the miRNA microarray.341 The results varied with
different cell types or HIV strains, making comparison of the
studies difficult.
In addition to affecting viral replication, cellular miRNAs
have also been reported to directly target HIV-1 regulatory
and accessory genes. A cluster of cellular miRNAs have been
shown to target the 3′ end of the HIV-1 RNA, common to
nearly all HIV-1 mRNA 3′-UTRs, to inhibit HIV-1 infection
of primary CD4 T cells. Termed the “anti-HIV miRNAs,”
this cluster includes miR-28, miR-125b, miR-150, miR-223,
and miR-382.342 Combined inhibition of these five miRNAs
increased virus production in CD4 T cells isolated from HIV-1+
individuals on highly active antiretroviral therapy (HAART),
indicating the miRNAs may be involved in maintaining
latent infection in resting CD4 T cells. Furthermore, another
group has shown that miR-150 and miR-223 are expressed
at high levels in CD4+ T cells isolated from healthy controls
compared with the HIV-1-infected individuals. 343 A study
using microarray to examine miRNA levels in the PBMC of
HIV-1+ individuals with high viral load found that miR-223
was downregulated in this patient population, but miR-150
expression was unchanged.344
It has been speculated that the anti-HIV miRNAs may
be reduced in the differentiation of monocytes to macrophages,
thereby creating an HIV-promoting intracellular environment.
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However, microarray studies showed that only miR-223 exhibited downregulation upon monocyte differentiation into macrophages. Meanwhile, miR-28-3p expression only slightly
declined, miR-125b and miR-382 did not differ from background levels, and miR-150 was strongly upregulated.345
Several studies have examined the role of the mi-R29
family during HIV infection, and target sites for miR-29a
and miR-29b have been predicted within the HIV-1 nef
3′-UTR.346,347 Inhibiting miR-29a in 293T cells enhanced
virus production and increased infectivity, while an miR-29a
mimic suppressed HIV-1 production.346 In support of this,
Patel et al noted that miR-29a levels were higher in PBMCs
from control patients than from HIV+ patients, suggesting a
possible role for miR-29a in HIV latency. Interestingly, plasma
levels of miR-29a showed an opposite trend.348
miRNAs as potential biomarkers of HIV infection. Several
groups have examined the regulation of cellular miRNAs
during HIV infection to validate the potential of miRNAs
as biomarkers (Table 11). Moreover, recent studies have
specifically examined the potential of miRNAs to distinguish between different groups of HIV-infected individuals. Munshi et al recently analyzed miR-16, miR-146b-5p,
miR-150, miR-191, and miR-223 levels in the PBMCs and
serum of HIV/AIDS patients in different stages of disease.
miR-150 and miR-146b-5p were found to distinguish HIV+
individuals as well as those on HAART or developing drug
resistance. The levels of miR-150 were found to be decreased
in the PBMCs of HIV/AIDS patients before treatment, and
HAART was able to restore levels of miR-150. Individuals
who developed drug resistance reduced miR-150 expression to
the levels observed in the symptomatic HIV/AIDS patients. 349
In contrast, plasma levels of miR-150 were increased during
infection and reduced upon treatment, prompting the authors
to propose that miR-150 in the plasma may be derived from
damaged tissues or released exosomes. A positive trend was
also generally observed between PBMC miR-150 and CD4
T cell counts.
Some individuals infected with HIV, known as elite suppressors (ES), maintain an undetectable viral load and high
CD4 T cell counts in the absence of any treatment. A study
that characterized the miRNAs present in the PBMCs of ES

versus untreated HIV/AIDS patients determined that the two
groups actually share expression patterns of several miRNAs,
although a few miRNAs were differentially expressed. miR-31,
miR-31*, and miR-150 were significantly downregulated,
while miR-155 and miR-22 were moderately upregulated in
active HIV/AIDS versus ES patients. 350 This study also found
a correlation of particular miRNAs with CD4 T cells counts
in infected individuals compared to uninfected controls: miR181b (negative) and miR-31, miR-31*, miR-29a, and miR-150
(positive) all significantly correlated with CD4 T cell count
(P , 0.05). Recently, Reynoso et al performed a similar study
examining miRNAs in the plasma of ES versus chronically
infected individuals and normal donors. No significant
differences were noted between normal and ES donors,
although miR-29b-3p, miR-33a-5p, and miR-146a-5p were
upregulated in ES versus chronically infected patients. Several miRNAs were also identified that correlated with CD4
T cell counts.351
While viral titers and CD4 T cell counts are important
for predicting disease progression, it has been suggested that
CD4 T cell counts do not necessarily correlate well with virologic failure in patients being treated with ART, 352 emphasizing the importance of the characterization and validation of
potential HIV biomarkers.
Potential miRNA therapeutics for HIV. At first thought, the
cluster of anti-HIV miRNAs (miR-28, miR-125b, miR-150,
miR-223, and miR-382) is of interest as potential antiretroviral
drugs due to their reported ability to target HIV-1 mRNAs.
However, several of these miRNAs are expressed in normal
CD4 T cells, 353 which are still capable of being infected by
HIV. Recently, Whisnant et al found that HIV-1 transcripts
are refractory to miRNA binding, likely due to secondary
structure of viral mRNAs.20 This implied that these anti-HIV
miRNAs may not be able to target the virus directly. This
does not preclude their possible role, however, in modulating
expression of genes that could create a cellular environment
that is not susceptible or permissive to infection. Considering that a single miRNA is capable of affecting the transcription of many genes and therefore possibly inducing off-target
effects, additional research is warranted concerning the utility
of miRNAs as antiretroviral drugs.

Table 11. Biomarker potential of host miRNAs associated with HIV-1 infection (.2-fold change in miRNA): selected studies.
Sample type

miRNA upregulated

miRNA downregulated

References

HIV-infected CD4+CD8- PBMCs

miR-223

miR-29a/b, miR-155, miR-21

446

HIV-infected Jurkat cells

miR-122, miR-297, miR-370,
miR-373*

miR17/92 cluster

339

miR-15b, miR-23a, miR-23b, miR-26a, miR27a,
miR-92, miR-144, miR-210, miR-320, miR-337,
miR-342, miR-451

447

miR-31, miR-31*, let-7 g, miR- 125b, miR-150

350

PBMCs from HIV-infected patients

PBMCs from HIV-infected patients

miR-9, miR-181b

Plasma and PBMCs from HIV-infected
patients

miR-150, miR-146b-5p

349
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Concluding Remarks

Over 200 biomarker-related clinical trials involving miRNAs
are listed on the Clinicaltrials.gov website (https://clinicaltrials.
gov/ct2/results?term=miRNA), demonstrating that miRNAs
continue to have great potential as biomarkers of diagnosis,
disease progression, and treatment efficacy. As such, the use
of miRNA biomarkers during diseases of viral origin also
warrants further investigation. Several DNA viruses of clinical importance, namely, herpesviruses and polyomaviruses,
encode unique viral miRNAs that could prove promising to
differentiate viruses that have similar clinical symptoms. The
use of miRNAs specifically expressed at different stages of
infection could also help in accurately determining disease
status. For the RNA viruses or retroviruses described above,
profiling panels of cellular miRNAs could provide a means
of identifying viruses or classifying disease stage. miRNAs
that can be detected in PBMCs, plasma, or exosomes and
mirror expression at the local site of infection or pathology
are particularly attractive, providing a means to avoid invasive biopsies and better monitor disease using less-invasive
methods. However, future miRNA assays based upon nextgeneration sequencing will require additional technical
expertise and standardization. In addition, the presence of
specific miRNAs in individuals of different backgrounds has
not been thoroughly studied, and the conservation of miRNAs between clinical strains of the same virus also needs to
be further explored.
Elucidating the biological functions of specific miRNAs
has allowed us to contemplate the role of specific miRNAs as
therapeutics or as therapeutic targets. However, drugs based
upon RNAi have not been without multiple technical difficulties, including vehicle design, antisense oligonucleotide biostability, targeted delivery to cells of interest (and to necessary
intracellular compartments), and off-target effects. Nonetheless, new strategies have been and continue to be developed
to combat these initial roadblocks and build better therapeutics.354,355 Preliminary results from Phase 2a studies of miravirsen, an LNA that targets miR-122 during HCV infection,
are cautiously promising.255 The results of additional clinical trials of miravirsen and other antagomirs will be of great
interest in ascertaining the therapeutic potential of miRNAs
and their inhibitors.
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